CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tuoxin Pharmaceutical Group Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tuoxin Pharmaceutical Group Co Ltd
No. 515 Kelong Avenue, Hongqi District
Phone: +86 3736351918p:+86 3736351918 Xinxiang, HEN  453000  China Ticker: 301089301089
Business Summary
Tuoxin Pharmaceutical Group Co Ltd, formerly Xinxiang Tuoxin Pharmaceutical Co Ltd, is a Chinese company mainly engaged in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates. The Company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series and other series of nucleoside (acid) products, including citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, uridine and other raw materials and pharmaceutical intermediates. Its products are mainly used in the fields of virus, anti-tumor and nervous system drugs. The Company mainly distributes its products in domestic market and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board XiningYang 61 4/1/2020 12/1/2011
Chief Financial Officer HuijuanJiao 57 5/1/2019 5/1/2019
General Manager, Director ShaohuaYang 29 1/5/2024 12/19/2023
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,550 (As of 12/31/2023)
Outstanding Shares: 126,544,500 (As of 3/31/2024)
Shareholders: 28,241
Stock Exchange: SHE
Fax Number: +86 3736351918


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024